Study on the Mechanism of Yifei Moxibustion Improving Immune Function in COPD Based on Plasma Exosome miRNAs
Recruiting · NCT07131020 · Interventional (participants receive a specific treatment) · Lead sponsor: Henan University of Traditional Chinese Medicine
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This study adopted a randomized controlled design, enrolling 90 patients and 30 healthy volunteers. The patients were randomly divided into the Yifei Moxibustion group, the conventional Western medicine treatment group, and the TCM syndrome differentiation treatment group, and were treated for 3 months. Peripheral venous blood was collected from both the healthy volunteers and the patients to observe indicators such as T cell subsets and immunoglobulins, to evaluate the effect of Yifei Moxibustion on improving immune function. The regulation of target genes by exosomes and potential action targets and molecular mechanisms were preliminarily verified through techniques such as nanoparticle tracking technology and flow cytometry.
Who can take part
Inclusion criteria
- Patients who meet the diagnostic criteria for stable chronic obstructive pulmonary disease;
- Patients who meet the TCM diagnostic criteria for lung qi deficiency, lung-spleen qi deficiency, and lung-kidney qi deficiency; ③ Aged 18 to 80 years old; ④ Voluntarily signed the informed consent form.
Exclusion criteria
- Pregnant and lactating women;
- Patients with cognitive impairment, confusion, dementia, or various mental disorders;
- Patients with unstable angina pectoris or acute myocardial infarction;
- Patients with a history of syncope after exercise or bone and joint diseases that affect exercise; ⑤ Patients with pneumothorax, pleural effusion, pulmonary embolism, or tumors;
- Patients known to be allergic to the ingredients of the moxibustion powder.
Where it is running
1 location listed.
- the First Affiliated Hospital of Henan University of Chinese Medicine - Zhengzhou, Henan, China